Clinical trial

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

Name
18054
Description
This study is a single centre intervention study to compare two methods of determining the measured glomerular filtration rate (mGFR). Subjects who receive radioactively labeled iothalamate (125I) and hippuran (131I) within the framework of routine clinical care, will be co-administered iohexol. The primary trial endpoint is the mGFR when administered 125I-iothalamate and 131I-hippuran versus iohexol. By determining the mGFR using both iohexol and iothalamate in the same patients, a direct comparison of the two methods can be made in terms of their accuracy and precision. This makes it possible to determine the potential use of the non-radioactive measurement method as an alternative to the radioactive method and thus lower the overall radioactive burden for patients and personnel.
Trial arms
Trial start
2024-06-01
Estimated PCD
2025-09-01
Trial end
2025-09-01
Status
Not yet recruiting
Treatment
Iohexol
Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
Arms:
Iohexol in addition to 125I-iothalamate and 131I-hippuran
125I-iothalamate and 131I-hippuran
Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
Arms:
Iohexol in addition to 125I-iothalamate and 131I-hippuran
Size
208
Primary endpoint
mGFR Iohexol
Through study completion, an average of 1 year
mGFR Iothalamate and hippuran
Through study completion, an average of 1 year
Eligibility criteria
Inclusion Criteria: * Scheduled to undergo a kidney function measurement test as part of standard care. * Written informed consent. Exclusion Criteria: * History of hypersensitivity to iodinated contrast media or one of the excipients in the formulation of iohexol (trometamol, sodium calcium edetate, hydrochloric acid). * Subjects with (suspected or known) thyrotoxicosis. * Pregnant women and women of child-bearing potential who are not using reliable contraception. * Patients who are unlikely to comply to the trial's procedure (non-compliance).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 208, 'type': 'ESTIMATED'}}
Updated at
2024-03-13

1 organization

1 product

3 indications

Product
Iohexol
Indication
Diagnosis